"Monoclonal Antibodies for Treatment of Multiple Myeloma. Emphasis on the CD38 Antibody Daratumumab "

• Status: Completed
• Trial end date: 2015-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Daratumumab is a new treatment for patients with myeloma. While many patients benefit from this treatment some do not and the mechanism(s) of failure are poorly understood. This study aims to clarify aspects of resistance to treatment with daratumumab in order to improve patient outcomes in the future.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Vejle Hospital
• Treatments: Antibodies; Antibodies, Monoclonal; BB 1101; Daratumumab; Dexamethasone; Dexamethasone 21-phosphate; Dexamethasone acetate; Immunoglobulins; Lenalidomide

Criteria

Inclusion Criteria:

• Accepted for a clinical trial with Daratumumab for myeloma

Exclusion Criteria:

• None